Data as of Aug 29
| +0.76 / +2.06%|
The 5 analysts offering 12-month price forecasts for KYTHERA Biopharmaceuticals Inc have a median target of 56.00, with a high estimate of 62.00 and a low estimate of 41.00. The median estimate represents a +48.90% increase from the last price of 37.61.
The current consensus among 5 polled investment analysts is to Buy stock in KYTHERA Biopharmaceuticals Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.